Stock Taper 
SCYX
$5.39
▼ DOWN 2.36% (-0.13)
KEY STATISTICS
Market Cap$33.90 M
52w High$10.48
52w Low$3.53
Dividend Yield—
Frequency—
P/E-1.58
Volume56.83K
Shares Out.6.29M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
David Gonzalez Angulo
COMPENSATION 2026
Salary$626,041
Stock Awards$283,961
Incentive Plan Pay$312,370
All Other Comp.$10,500
Total$1,540,181
ABOUT
SECTOR
Healthcare
WENT PUBLIC
May 2, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
18
UPCOMING EARNINGS
DateNov 4, 2026
DayWednesday
Rev. Est.$98.00K
NOV
4
WED
SPLIT RECORD
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-06-01 | Reverse | 1:8 |
| 2020-07-17 | Reverse | 1:10 |
PRICE
$5.39 ▼ DOWN 2.36% (−$0.13)About SCYNEXIS, Inc.
https://www.scynexis.com ↗SCYNEXIS, Inc. is a biotech company developing and commercializing antifungal treatments like BREXAFEMME and Ibrexafungerp for various fungal infections, with ongoing research collaborations and a focus on innovative oral and IV therapies.
INDUSTRY
Medical - Pharmaceuticals
A PRODUCT SCYNEXIS, INC. IS KNOWN FOR
Brexafemme (ibrexafungerp)
A first-in-class oral antifungal for vulvovaginal candidiasis and recurrence reduction, it’s the first new oral antifungal class in over 20 years, licensed exclusively to GSK for global commercialization and development.
Revenue by Products
| Icon | PRODUCT | Q2-2025 | Q3-2025 | Q4-2025 | Q2-2026 |
|---|---|---|---|---|---|
 | License and Service | $1.36M | $334K ▼ | $17.2M ▲ | $235K ▼ |
Revenue by Geography
| Map | REGION | FY2014 | FY2015 | FY2016 |
|---|---|---|---|---|
 | Other NonUS | $1.37M | $257K ▼ | $257K |
 | Europe | $1.24M | $477K ▼ | $0 ▼ |
 | UNITED STATES | $16.42M | $6.93M ▼ | $0 ▼ |
ETFS HOLDING THIS STOCK
ETFS HOLDING
14
LISTED HERE
3
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
100.00%
HOLDERS
72
TOP 12 OF 72 · RANKED BY POSITION SIZE
Great Point Partners LLC
Avidity Partners Management LP
Kingdon Capital Management, L.L.C.
Heights Capital Management, Inc
Goldman Sachs Group Inc
Empery Asset Management, LP
Vanguard Group Inc
Federated Hermes, Inc.
Dafna Capital Management LLC
Acadian Asset Management LLC
Millennium Management LLC
Decheng Capital Management Iii (Cayman), LLC
RATINGS SNAPSHOT
Overall rating: C+
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book4
Overall Score2
INSIDER TRADES
★
DIRECTOR
HASTINGS DAVID C
Purchase · 2.9K shares
2026-06-26
★
DIRECTOR
Tinmouth Brian Philippe
Purchase · 2.9K shares
2026-06-26
★
DIRECTOR
Tinmouth Brian Philippe
Purchase · 2.9K shares
2026-06-26
★
DIRECTOR
HANHAM ANN
Purchase · 2.9K shares
2026-06-26
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
SECTORS PEERS
| PEER | PRICE | |
|---|---|---|
 NRXS | $6.00 | COMPARE |
 TLPH | $1.20 | COMPARE |
 NRSN | $0.42 | COMPARE |
 COSM | $0.22 | COMPARE |
 XCUR | $1.29 | COMPARE |
 NXL | $0.25 | COMPARE |
 CVKD | $1.54 | COMPARE |
 CLGN | $0.36 | COMPARE |